Disease or Syndrome
Eikon and Veradermics Announce IPO Targets Amid Biotech Market Optimism
Eikon Therapeutics; Veradermics; IPO; biotech; hair loss; cancer drugs; Nasdaq; NYSE
HHS Issues Guidance to Shield Pharma from Anti-Kickback Violations in TrumpRx Direct-to-Consumer Drug Sales
TrumpRx; HHS; anti-kickback statute; direct-to-consumer; prescription drugs; OIG bulletin
Spotlight On: AI in Genomics and Multimodal Data Analysis Loosens Orphan Drug R&D Bottlenecks
AI; genomics; multimodal data; orphan drugs; rare diseases; drug discovery; drug repurposing
Unravel Biosciences and The SCN2A Foundation Announce Drug Discovery Collaboration
Unravel Biosciences; SCN2A Foundation; drug discovery; SCN2A mutations; autism; epilepsy; loss-of-function; AI therapeutics
FDA Places Clinical Holds on Regenxbio’s RGX-111 and RGX-121 Gene Therapy Trials After Brain Tumor in Patient
FDA clinical hold; Regenxbio; RGX-111; RGX-121; brain tumor; gene therapy; MPS I; MPS II; AAV vector
Surge in Investments Driving Genetic and Pharma Innovations in 2026
genetic medicines; pharma investments; gene therapy; biomanufacturing; venture capital; rare diseases
Boehringer Ingelheim Advances Apecotrep to Phase 3 for Rare Kidney Disease FSGS Despite Mixed Mid-Stage Data
Boehringer Ingelheim; apecotrep; BI 764198; FSGS; Phase 3; Phase 2; proteinuria; TRPC6 inhibitor; kidney disease
CMS Selects Trulicity and Biktarvy Among 15 Drugs for Third Medicare Price Negotiation Cycle
CMS; Medicare negotiations; Trulicity; Biktarvy; drug pricing; Part B drugs; Trump administration
Boehringer Ingelheim Signs $1.3 Billion Deal for Simcere’s Preclinical IBD Bispecific SIM0709
Boehringer Ingelheim; Simcere; SIM0709; IBD; bispecific antibody; TL1A; IL-23p19; licensing deal
Insilico Medicine Secures Nearly $120M AI-Driven Cardiometabolic Drug Deal with Qilu Pharmaceutical
Insilico Medicine; Qilu Pharmaceutical; cardiometabolic; AI drug discovery; Pharma.AI; $120M deal